Experimental drug aims to rebuild immune defenses in rare disorder
NCT ID NCT05600920
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests an experimental drug called NT-I7 in people with idiopathic CD4 lymphopenia (ICL), a condition where low CD4 immune cells lead to severe infections and other diseases. The goal is to see if NT-I7 can safely increase CD4 cell counts. About 60 adults aged 18–75 will receive three injections over 12 weeks, with regular blood tests and follow-ups for a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.